Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Apr;37(4):896–900. doi: 10.1128/aac.37.4.896

In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.

T Lawrence 1, C Rotstein 1, T R Beam Jr 1, E A Gorzynski 1, D Amsterdam 1
PMCID: PMC187804  PMID: 8494388

Abstract

The susceptibilities of 316 gram-positive bacteremic isolates to ramoplanin, vancomycin, and teicoplanin and seven other antibiotics were tested. Ramoplanin demonstrated MICs of < or = 0.25 microgram/ml for at least 99% of Staphylococcus aureus isolates and 100% of coagulase-negative staphylococci tested. For both oxacillin-susceptible and oxacillin-resistant S. aureus and coagulase-negative staphylococci, the activity of ramoplanin surpassed those of both vancomycin and teicoplanin. Ramoplanin and teicoplanin had comparable activities against enterococci and Streptococcus pneumoniae and were superior to vancomycin.

Full text

PDF
896

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992 Jul;15(1):77–83. doi: 10.1093/clinids/15.1.77. [DOI] [PubMed] [Google Scholar]
  2. Banerjee S. N., Emori T. G., Culver D. H., Gaynes R. P., Jarvis W. R., Horan T., Edwards J. R., Tolson J., Henderson T., Martone W. J. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med. 1991 Sep 16;91(3B):86S–89S. doi: 10.1016/0002-9343(91)90349-3. [DOI] [PubMed] [Google Scholar]
  3. Bartoloni A., Colao M. G., Orsi A., Dei R., Giganti E., Parenti F. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. J Antimicrob Chemother. 1990 Nov;26(5):627–633. doi: 10.1093/jac/26.5.627. [DOI] [PubMed] [Google Scholar]
  4. Brummett R. E., Fox K. E. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother. 1989 Jun;33(6):791–796. doi: 10.1128/aac.33.6.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dixson S., Brumfitt W., Hamilton-Miller J. M. In vitro evaluation of ramoplanin (MDL 62198, A 16686) Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):819–821. doi: 10.1007/BF01975062. [DOI] [PubMed] [Google Scholar]
  6. Downs N. J., Neihart R. E., Dolezal J. M., Hodges G. R. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med. 1989 Aug;149(8):1777–1781. [PubMed] [Google Scholar]
  7. Johnson C. C., Taylor S., Pitsakis P., May P., Levison M. E. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob Agents Chemother. 1992 Oct;36(10):2342–2345. doi: 10.1128/aac.36.10.2342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jones R. N., Barry A. L. In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use. Diagn Microbiol Infect Dis. 1989 May-Jun;12(3):279–282. doi: 10.1016/0732-8893(89)90029-1. [DOI] [PubMed] [Google Scholar]
  9. Maple P. A., Hamilton-Miller J. M., Brumfitt W. Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus. J Antimicrob Chemother. 1989 Apr;23(4):517–525. doi: 10.1093/jac/23.4.517. [DOI] [PubMed] [Google Scholar]
  10. Mellor J. A., Kingdom J., Cafferkey M., Keane C. T. Vancomycin toxicity: a prospective study. J Antimicrob Chemother. 1985 Jun;15(6):773–780. doi: 10.1093/jac/15.6.773. [DOI] [PubMed] [Google Scholar]
  11. O'Hare M. D., Felmingham D., Grüneberg R. N. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp. Drugs Exp Clin Res. 1988;14(10):617–619. [PubMed] [Google Scholar]
  12. Schaberg D. R., Culver D. H., Gaynes R. P. Major trends in the microbial etiology of nosocomial infection. Am J Med. 1991 Sep 16;91(3B):72S–75S. doi: 10.1016/0002-9343(91)90346-y. [DOI] [PubMed] [Google Scholar]
  13. Swenson J. M., Facklam R. R., Thornsberry C. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species. Antimicrob Agents Chemother. 1990 Apr;34(4):543–549. doi: 10.1128/aac.34.4.543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Uttley A. H., Collins C. H., Naidoo J., George R. C. Vancomycin-resistant enterococci. Lancet. 1988 Jan 2;1(8575-6):57–58. doi: 10.1016/s0140-6736(88)91037-9. [DOI] [PubMed] [Google Scholar]
  15. Wenzel R. P., Nettleman M. D., Jones R. N., Pfaller M. A. Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am J Med. 1991 Sep 16;91(3B):221S–227S. doi: 10.1016/0002-9343(91)90372-5. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES